Immatics NV logo

Immatics NVNASDAQ: IMTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Germany

IPO:

12 December 2018

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$973.32 M
-32%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
62%vs. sector
-52%vs. 3y high
79%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:44:16 GMT
$9.44+$0.34(+3.74%)

Dividend

No data over the past 3 years
$20.19 M$17.53 M
$20.19 M-$19.41 M

Analysts recommendations

Institutional Ownership

IMTX Latest News

Immatics: A Promising TCR Pipeline
seekingalpha.com11 October 2024 Sentiment: POSITIVE

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.

Immatics Announces Pricing of $150 Million Public Offering
globenewswire.com10 October 2024 Sentiment: POSITIVE

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
benzinga.com10 October 2024 Sentiment: NEUTRAL

On Thursday, Immatics N.V.  IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.

Immatics Announces Proposed $150 Million Public Offering
globenewswire.com10 October 2024 Sentiment: NEUTRAL

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
globenewswire.com10 October 2024 Sentiment: POSITIVE

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
globenewswire.com04 October 2024 Sentiment: POSITIVE

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
globenewswire.com16 September 2024 Sentiment: POSITIVE

Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
globenewswire.com06 September 2024 Sentiment: POSITIVE

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research.

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com13 August 2024 Sentiment: POSITIVE

Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.

Immatics Announces Second Quarter 2024 Financial Results and Business Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024.

  • 1(current)

What type of business is Immatics NV?

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

What sector is Immatics NV in?

Immatics NV is in the Healthcare sector

What industry is Immatics NV in?

Immatics NV is in the Biotechnology industry

What country is Immatics NV from?

Immatics NV is headquartered in Germany

When did Immatics NV go public?

Immatics NV initial public offering (IPO) was on 12 December 2018

What is Immatics NV website?

https://www.immatics.com

Is Immatics NV in the S&P 500?

No, Immatics NV is not included in the S&P 500 index

Is Immatics NV in the NASDAQ 100?

No, Immatics NV is not included in the NASDAQ 100 index

Is Immatics NV in the Dow Jones?

No, Immatics NV is not included in the Dow Jones index

When was Immatics NV the previous earnings report?

No data

When does Immatics NV earnings report?

The next expected earnings date for Immatics NV is 14 November 2024